Kartesia, the European specialist provider of capital solutions for small and mid-sized companies, is pleased to announce that it has completed a 12m€ capital increase in ADL Biopharma (“ADL”) and has become the sole shareholder of the Spanish biopharmaceutical company, which focuses on the development and production of pharma APIs and specialty ingredients for the food, flavour and fragances markets.
Kartesia, the European specialist provider of capital solutions for small and mid-sized companies, is pleased to announce the completion of a new investment in Universidad Católica de Murcia (“UCAM” or the “Company”) through its Kartesia Senior Opportunities (“KSO”) strategy, to support the Company’s growth plans.
Kartesia is pleased to announce that it has reached an agreement with ADL Bionatur Solutions and BTC to acquire a 51% stake in ADL Biopharma (“ADL”), a Spanish biopharmaceutical company focused on the development and production of antibiotics and precision fermentation processes.
Kartesia is pleased to announce that the investment of the Altercap II funds into the senior and mezzanine debt issued by URSA was repaid at par following the sale of the Company to Xella International.
Kartesia is pleased to announce that the investment of the KCO III fund into the senior debt issued by Grupo Cortefiel was repaid at par following a refinancing in the context of the reinvestment of PAI Partners and CVC Capital Partners.
Kartesia has invested €25 million in the Spanish insurance software group Vet+a, a software company specialised in the provision of appraisal and claim management solutions for home and property insurers.
At Kartesia we try to be more than a typical lender by reviewing new business opportunities with our clients. As a credit platform operating in France, the UK, Spain, Germany, Italy and Austria, we enjoy a deep network of top managers and experts and we ensure our clients make the most of it.